Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.Read more
Serodus ASA is a Scandinavian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs.Serodus strives to increase shareholders value through advancing its portfolio to value-creating clinical milestones. With the current drug candidates supported by exceptional competencies to develop them, Serodus is uniquely positioned for successRead more
XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, enabling the treatment of organs and maintaining organs in good condition outside the body pending transplantation.Read more
Headquartered in Copenhagen, Sunstone Capital is an early-stage Life Science and Technology venture capital company investing in European start-up companies with strong potential to achieve global success in their markets. Since our establishment in 2007, we have built a strong portfolio currently totaling 50 companies and have completed several successful trade sales and IPOs.Read more
Boynton Angels is a group of Angel investors focused on investing in expansion stage companies in New England with a particular focus on endeavors located within a two-hour radius of Worcester, Massachusetts. Boynton Angels is a member of the Angel Capital Association, following best practice guidelines along with 100 similar organizations in the United States.Read more
Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flows or get acquired.Read more